BRAIN CANCER ENQUIRIES
Melanoma Institute Australia (MIA) has received many enquiries regarding the treatment given to one of our Co-Medical Directors, Prof Richard Scolyer AO, who has been diagnosed with brain cancer. We understand the difficult situation faced by many brain cancer patients and their families and the many people who have been following Prof Scolyer’s journey. However, we are unfortunately not in a position to respond to individual enquiries seeking advice about access to brain cancer treatment or enrolment onto brain cancer clinical trials.
MIA is a melanoma and skin cancer research and treatment centre, and we do not provide clinical consultation or conduct clinical trials in relation to brain cancer. We strongly advise all brain cancer patients to continue to consult with their own medical teams.
Data generated from the experimental treatment given to Prof Scolyer has been submitted for publication in a leading medical journal and is currently undergoing external peer review. It is hoped that this data will prompt leading institutions within the brain cancer sector to open new clinical trials in the near future.
Our melanoma patients remain at the centre of everything we do here at MIA as we continue to strive towards achieving our mission of zero deaths from melanoma.
Matthew Browne
Chief Executive Officer
24 June 2024
LATEST NEWS
Get on board with sun safety
Announcing a partnership between MIA and the Boating Industry Association (BIA) to promote sun safety amongst boating enthusiasts, including MIA hosting a stand at the Sydney International Boat Show in August.
A month of inspiring Community Fundraising
Read more about the inspiring stories behind our Community Fundraisers. Find out how you can fundraise to support melanoma research, which is also impacting other cancers.
What a night at MIA Amie St Clair Gatsby Ball!
Enjoy all the pics from the MIA Amie St Clair Gatsby Ball, held in Wagga Wagga on Saturday 29 June..
Our photo tribute to Kay Van Norton Poche AO
Pictures tell a thousand words, and we are proud to share this photo tribute of Kay and her friendship with us over many years.
Preventing disease recurrence in BRAF positive melanoma patients
Final results of the COMBI-AD clinical trial, published in New England Journal of Medicine, show significant benefit in preventing disease progression in BRAF positive Stage III melanoma patients.
MIA’s MISSION
ZERO DEATHS FROM MELANOMA
MIA will achieve its mission through 3 pillars of action: Research, Clinical Care & Education.
MIA conducts its research under 4 themes: Prevention, Risk & Clinical Detection – Early Melanoma – Advanced Melanoma – Supportive Care & Survivorship.
1300
It is estimated 1300 Australians will die from melanoma this year
30 mins
1 Australian is diagnosed with melanoma every 30 minutes
90%
If caught early 90% of melanomas can be cured by surgery
Age 20-39
Melanoma is the most common cancer affecting Australians aged 20 to 39
